
Biogen (BIIB) Stock Forecast & Price Target
Biogen (BIIB) Analyst Ratings
Bulls say
Biogen has experienced a notable 35% increase in stock value since the beginning of the third quarter of 2025, in line with a broader rally in the biopharma sector, indicating a positive market sentiment towards the company. The successful execution of commercial strategies for new product launches, particularly Leqembi, Skyclaris, and Zurzuvae, has resulted in revenue contributions that exceed consensus expectations, providing optimism for the company's near-term earnings potential. With revenue generation forecasts suggesting that key product launches could contribute $2.5 to $3.0 billion by 2030, Biogen is well-positioned for future growth driven by its evolving pipeline and strategic business development initiatives, despite the challenges posed by its declining multiple sclerosis franchise.
Bears say
Biogen's financial outlook is negatively influenced by anticipated declines in its multiple sclerosis (MS) franchise, which is projected to face intensified competition from upcoming biosimilars, leading to an estimated 5-8% decrease in global MS revenues in the second half of 2025. The company's revenue growth is expected to remain largely flat with a compound annual growth rate (CAGR) of nearly zero from 2026 to 2030, primarily due to erosion in the MS business and decreasing royalties from Ocrevus starting in 2029. Additionally, pressure on other product lines, such as Skyclarys, alongside elevated difficulties in clinical trials for lupus treatments, further exacerbates concerns regarding Biogen's long-term profitability and growth prospects.
This aggregate rating is based on analysts' research of Biogen and is not a guaranteed prediction by Public.com or investment advice.
Biogen (BIIB) Analyst Forecast & Price Prediction
Start investing in Biogen (BIIB)
Order type
Buy in
Order amount
Est. shares
0 shares